Your session is about to expire
← Back to Search
Glutamate Receptor Antagonist
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
Phase 2
Waitlist Available
Research Sponsored by Addex Pharma S.A.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 2
Summary
This trial is testing a medication called dipraglurant to help people with blepharospasm, a condition causing involuntary eye muscle contractions. The study will check if the medication is safe and if it can reduce the severity and frequency of these muscle spasms. Dipraglurant works by blocking certain brain signals that cause the spasms.
Eligible Conditions
- Blepharospasm
- Limb Dystonia
- Eyelid Twitching
- Dystonia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to day 2
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 2
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Computerized Motor Objective Rater (CMOR) analysis of blinking activity
Safety and tolerability of dipraglurant as measured by incidence of adverse events
Skintronics wearable analysis of blinking activity
Secondary study objectives
Blepharospasm Disability Index (BSDI)
Blepharospasm Phenotyping Tool (BPT)
Blepharospasm Severity Rating Scale (BSRS)
+5 moreTrial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Dipraglurant 50 mgExperimental Treatment1 Intervention
Group II: Dipraglurant 100 mgExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Find a Location
Who is running the clinical trial?
Addex Pharma S.A.Lead Sponsor
7 Previous Clinical Trials
1,143 Total Patients Enrolled